"Methylphenidate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
| Descriptor ID |
D008774
|
| MeSH Number(s) |
D02.241.223.601.600 D03.383.621.460
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Methylphenidate".
Below are MeSH descriptors whose meaning is more specific than "Methylphenidate".
This graph shows the total number of publications written about "Methylphenidate" by people in this website by year, and whether "Methylphenidate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2003 | 3 | 0 | 3 |
| 2005 | 4 | 0 | 4 |
| 2006 | 3 | 0 | 3 |
| 2007 | 5 | 1 | 6 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 1 | 3 |
| 2011 | 6 | 1 | 7 |
| 2012 | 3 | 0 | 3 |
| 2013 | 4 | 0 | 4 |
| 2014 | 2 | 0 | 2 |
| 2015 | 3 | 0 | 3 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 2 | 1 | 3 |
| 2020 | 2 | 0 | 2 |
| 2021 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Methylphenidate" by people in Profiles.
-
Plasma Carboxylesterase 1 Predicts Methylphenidate Exposure: A Proof-of-Concept Study Using Plasma Protein Biomarker for Hepatic Drug Metabolism. Clin Pharmacol Ther. 2022 04; 111(4):878-885.
-
Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial. JAMA Neurol. 2021 11 01; 78(11):1324-1332.
-
a2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder. JAMA. 2021 05 25; 325(20):2067-2075.
-
Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A Comparison of Instruments. Am J Geriatr Psychiatry. 2021 01; 29(1):81-89.
-
Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate. Am J Geriatr Psychiatry. 2021 01; 29(1):51-62.
-
Young Children with Attention-Deficit/Hyperactivity Disorder and/or Disruptive Behavior Disorders Are More Frequently Prescribed Alpha Agonists Than Stimulants. J Child Adolesc Psychopharmacol. 2020 03; 30(2):81-86.
-
Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications. Sleep Med. 2020 04; 68:97-109.
-
Potential for Underestimation of d-Methylphenidate Bioavailability Using Chiral Derivatization/Gas Chromatography. Drug Metab Dispos. 2019 07; 47(7):764-767.
-
Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations. Pharmacotherapy. 2019 06; 39(6):677-688.
-
The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial. Trials. 2018 Jan 18; 19(1):46.